Chronic myelogenous leukemia initiating cells require Polycomb group protein EZH2

Tyrosine kinase inhibitors (TKIs) have revolutionized chronic myelogenous leukemia (CML) management. Disease eradication, however, is hampered by innate resistance of leukemia initiating cells (LICs) to TKI-induced killing, which also provides the basis for subsequent emergence of TKI-resistant muta...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Cancer Discov
Hoofdauteurs: Xie, Huafeng, Peng, Cong, Huang, Jialiang, Li, Bin E., Kim, Woojin, Smith, Elenoe C., Fujiwara, Yuko, Qi, Jun, Cheloni, Giulia, Das, Partha P., Nguyen, Minh, Li, Shaoguang, Bradner, James E., Orkin, Stuart H.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2016
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5096974/
https://ncbi.nlm.nih.gov/pubmed/27630126
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-15-1439
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items